Antiretroviral effect of a gag-RNase HI fusion gene

G. Schumann, K. Cannon, W. P. Ma, R. J. Crouch, J. D. Boeke

Research output: Contribution to journalArticle

Abstract

We have previously shown that a molecule consisting of a fusion of a Ca2+-dependent nuclease (from Staphylococcus aureus) to a retroviral coat protein specifies a potent anti-viral specific for that retrovirus. Genes specifying such fusion proteins can be delivered to virus-susceptible cells, providing an antiviral gene therapy aimed at limiting virus spread. We report here the results of experiments to vary the nuclease moiety of such fusion proteins. We found that one nuclease, Serratia marcescens nuclease, was extremely toxic to host cells and hence not likely to be useful for therapeutic purposes. A second nuclease, Escherichia coli RNase HI was found to be nontoxic and highly effective against a murine leukemia virus when it was fused to the leukemia virus coat protein. The fusion protein was enzymatically active and stably expressed, without apparent toxicity to host cells. Reduction in infectious virus output was as high as 97-99%. These studies provide a model system for the development of gene therapeutic agents aimed at combating retroviral infection in vivo.

Original languageEnglish (US)
Pages (from-to)593-599
Number of pages7
JournalGene Therapy
Volume4
Issue number6
StatePublished - 1997

Fingerprint

Gene Fusion
Viruses
Serratia marcescens nuclease
Capsid Proteins
Murine Leukemia Viruses
Proteins
Poisons
Retroviridae
Genetic Therapy
Genes
Antiviral Agents
Staphylococcus aureus
Leukemia
Escherichia coli
ribonuclease HI
Therapeutics
Infection

Keywords

  • Antiviral gene therapy
  • Murine leukemia virus
  • RCAS vectors
  • RNase HI
  • Serratia nuclease

ASJC Scopus subject areas

  • Genetics

Cite this

Schumann, G., Cannon, K., Ma, W. P., Crouch, R. J., & Boeke, J. D. (1997). Antiretroviral effect of a gag-RNase HI fusion gene. Gene Therapy, 4(6), 593-599.

Antiretroviral effect of a gag-RNase HI fusion gene. / Schumann, G.; Cannon, K.; Ma, W. P.; Crouch, R. J.; Boeke, J. D.

In: Gene Therapy, Vol. 4, No. 6, 1997, p. 593-599.

Research output: Contribution to journalArticle

Schumann, G, Cannon, K, Ma, WP, Crouch, RJ & Boeke, JD 1997, 'Antiretroviral effect of a gag-RNase HI fusion gene', Gene Therapy, vol. 4, no. 6, pp. 593-599.
Schumann G, Cannon K, Ma WP, Crouch RJ, Boeke JD. Antiretroviral effect of a gag-RNase HI fusion gene. Gene Therapy. 1997;4(6):593-599.
Schumann, G. ; Cannon, K. ; Ma, W. P. ; Crouch, R. J. ; Boeke, J. D. / Antiretroviral effect of a gag-RNase HI fusion gene. In: Gene Therapy. 1997 ; Vol. 4, No. 6. pp. 593-599.
@article{a0dd6fc8aaab4207927944e6221d8c0e,
title = "Antiretroviral effect of a gag-RNase HI fusion gene",
abstract = "We have previously shown that a molecule consisting of a fusion of a Ca2+-dependent nuclease (from Staphylococcus aureus) to a retroviral coat protein specifies a potent anti-viral specific for that retrovirus. Genes specifying such fusion proteins can be delivered to virus-susceptible cells, providing an antiviral gene therapy aimed at limiting virus spread. We report here the results of experiments to vary the nuclease moiety of such fusion proteins. We found that one nuclease, Serratia marcescens nuclease, was extremely toxic to host cells and hence not likely to be useful for therapeutic purposes. A second nuclease, Escherichia coli RNase HI was found to be nontoxic and highly effective against a murine leukemia virus when it was fused to the leukemia virus coat protein. The fusion protein was enzymatically active and stably expressed, without apparent toxicity to host cells. Reduction in infectious virus output was as high as 97-99{\%}. These studies provide a model system for the development of gene therapeutic agents aimed at combating retroviral infection in vivo.",
keywords = "Antiviral gene therapy, Murine leukemia virus, RCAS vectors, RNase HI, Serratia nuclease",
author = "G. Schumann and K. Cannon and Ma, {W. P.} and Crouch, {R. J.} and Boeke, {J. D.}",
year = "1997",
language = "English (US)",
volume = "4",
pages = "593--599",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Antiretroviral effect of a gag-RNase HI fusion gene

AU - Schumann, G.

AU - Cannon, K.

AU - Ma, W. P.

AU - Crouch, R. J.

AU - Boeke, J. D.

PY - 1997

Y1 - 1997

N2 - We have previously shown that a molecule consisting of a fusion of a Ca2+-dependent nuclease (from Staphylococcus aureus) to a retroviral coat protein specifies a potent anti-viral specific for that retrovirus. Genes specifying such fusion proteins can be delivered to virus-susceptible cells, providing an antiviral gene therapy aimed at limiting virus spread. We report here the results of experiments to vary the nuclease moiety of such fusion proteins. We found that one nuclease, Serratia marcescens nuclease, was extremely toxic to host cells and hence not likely to be useful for therapeutic purposes. A second nuclease, Escherichia coli RNase HI was found to be nontoxic and highly effective against a murine leukemia virus when it was fused to the leukemia virus coat protein. The fusion protein was enzymatically active and stably expressed, without apparent toxicity to host cells. Reduction in infectious virus output was as high as 97-99%. These studies provide a model system for the development of gene therapeutic agents aimed at combating retroviral infection in vivo.

AB - We have previously shown that a molecule consisting of a fusion of a Ca2+-dependent nuclease (from Staphylococcus aureus) to a retroviral coat protein specifies a potent anti-viral specific for that retrovirus. Genes specifying such fusion proteins can be delivered to virus-susceptible cells, providing an antiviral gene therapy aimed at limiting virus spread. We report here the results of experiments to vary the nuclease moiety of such fusion proteins. We found that one nuclease, Serratia marcescens nuclease, was extremely toxic to host cells and hence not likely to be useful for therapeutic purposes. A second nuclease, Escherichia coli RNase HI was found to be nontoxic and highly effective against a murine leukemia virus when it was fused to the leukemia virus coat protein. The fusion protein was enzymatically active and stably expressed, without apparent toxicity to host cells. Reduction in infectious virus output was as high as 97-99%. These studies provide a model system for the development of gene therapeutic agents aimed at combating retroviral infection in vivo.

KW - Antiviral gene therapy

KW - Murine leukemia virus

KW - RCAS vectors

KW - RNase HI

KW - Serratia nuclease

UR - http://www.scopus.com/inward/record.url?scp=0030764480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030764480&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 593

EP - 599

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 6

ER -